Pliant Therapeutics, Inc. (PLRX) Stock: Price, Forecast & Analyst Target
Pliant Therapeutics, Inc. (PLRX) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $0.62 (-6.20%), as of the Nov 19, 2026 trading session; market cap $38.4M.
Educational signal · not a buy or sell recommendation · How to read this
Pliant Therapeutics, Inc. · PLRX · NASDAQ
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrosis and related diseases.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Pliant Therapeutics (PLRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a fragile balance sheet and an expensive valuation, though growth is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 4 of the last 8 reports
- Altman Z -7.93 · Piotroski F 2
- ROE -50.3% · ROA -23.3% · current ratio 9.90
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.62 | |
| Change on the day | -6.20% | |
| 52-week range | $0.62 – $1.79 | |
| Market capitalisation | $38.4M | — |
| Shares traded on the day | 746.3K |
Price & events
Other perspectives
Council score for Pliant Therapeutics (PLRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Pliant Therapeutics (PLRX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pliant Therapeutics, Inc. (PLRX) is listed on NASDAQ. It employs 49 people and is led by Bernard Coulie. The market values it at $38.4M.
What do the latest results show for Pliant Therapeutics (PLRX)?
Short answer · as of
Against analyst estimates the company has EPS beat 4 of the last 8 reports.
What are the financial strengths and risks for Pliant Therapeutics (PLRX)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -7.93 · Piotroski F 2. Trailing ratios: ROE -50.3% · ROA -23.3% · current ratio 9.90.
Data-derived red flags
- Listing risk — at $0.62 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -7.93 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-50.3%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Pliant Therapeutics (PLRX)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $2.50M · EPS -1.44 · 5 analysts. Current published price targets run low $3.00 · high $3.00 · consensus $3.00 · median $3.00 against a quoted price of $0.62 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for PLRX.
Checked against the records this page reads, on the dates shown above.
How does Pliant Therapeutics compare with its peers?
Short answer
Pliant Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| Pliant Therapeutics (PLRX) — this page | $0.62 | $38.4M | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $3.00 – $3.00
- Consensus target
- $3.00
- Median target
- $3.00
- Revenue estimate
- $2.50M
- EPS estimate
- $-1.44
Consensus record · Captured .
Measured against a quoted price of $0.62 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PLRX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PLRX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Pliant Therapeutics (PLRX)?
- Pliant Therapeutics Announces Presentation of PLN-101095 Preclinical and Clinical Data at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
- Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
- Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)
- Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
Investor Questions: PLRX Stock
These answers are editorial: 1 of these 9 answers is drawn from the PLRX research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PLRX?
PLRX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PLRX a good stock to buy?
Stock Expert AI does not rate PLRX buy, sell or hold. Pliant Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PLRX stock price today?
The last price recorded for Pliant Therapeutics, Inc. (PLRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the PLRX price target?
The analyst consensus price target for Pliant Therapeutics, Inc. (PLRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are Pliant Therapeutics, Inc.'s strategies for commercializing its products?
Pliant Therapeutics, as a clinical-stage company, has not yet commercialized any products. Their commercialization strategy is likely to involve a combination of out-licensing and potential direct sales, depending on the specific product and market.
What are the key factors to evaluate for PLRX?
Pliant Therapeutics, Inc. (PLRX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. The company's approach centers on targeting integrins, a class of cell surface receptors that play a crucial role in the fibrotic process. Not financial advice.
How frequently does PLRX data refresh on this page?
PLRX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PLRX's recent stock price performance?
Pliant Therapeutics, Inc. (PLRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel integrin-targeted therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PLRX overvalued or undervalued right now?
Pliant Therapeutics, Inc. (PLRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 8 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com